MedTrace Logo

Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD

NCT02285218 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-03-18

No results posted yet for this study

Summary

To investigate the predictive roles of adipokines and hepatokines to detect non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia.

To examine the association or effects of clinical and biochemical factors (lab results and medication, etc.) on serum levels of adipokines and hepatokines in certain subjects with non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia.

Conditions

Interventions

OTHER

serum blood sampling

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2019-03-31
Completion
2019-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02285218 on ClinicalTrials.gov